Syndeio Biosciences is a biotechnology company developing novel therapies for neuropsychiatric and cognitive disorders by focusing on fundamental synapse biology. The company utilizes its proprietary Boost Platform™ to engineer drug candidates with differentiated mechanisms of action, such as event-driven pharmacology, to strengthen neuronal connections. Their pipeline aims to restore brain health by targeting synaptic dysfunction driving conditions like depression and Alzheimer's disease.
Funding
$90M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neuropsychiatric and cognitive disorders, often characterized by synaptic weakening and loss, affect over one billion people globally. Current therapeutic approaches for these conditions have limitations in efficacy and speed of action.
Solution
Syndeio Biosciences is developing a new class of transformative treatments for neuropsychiatric and cognitive disorders by focusing on synaptic biology. The company's proprietary Boost platform provides deep insights into synapse pharmacology, enabling the creation of drug candidates with differentiated mechanisms of action. Syndeio's approach leverages event-driven pharmacology, where a single drug dose can induce lasting biological changes that strengthen neuronal connections. This strategy aims to deliver rapid-acting, safe, and effective therapies by enhancing synaptic health and restoring neural connectivity.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel treatments for central nervous system disorders, particularly those involving synaptic dysfunction.
Features
- **Boost™ Platform**: A proprietary synapse pharmacology platform that integrates molecular, functional, and behavioral models to understand how molecules impact neuronal networks and synaptogenesis.
- **Event-Driven Pharmacology**: A mechanism designed to trigger lasting biological changes with a single drug dose, strengthening neuronal connections.
- **Zelquistinel**: An oral molecule in Phase 2 development for major depressive disorder (MDD) and planned for a synaptic function biomarker trial in Alzheimer's disease. It acts as a positive allosteric modulator (PAM) of the NMDA receptor (NMDAR), enhancing glutamate signaling.
- **Apimostinel**: An injectable NMDAR PAM being evaluated for acute treatment of depression, with potential for longer-lasting outcomes when paired with digital therapy.
- **Precision Neuroscience Approach**: Utilizes objective biomarkers, quantitative EEG, brain wave analysis, machine learning, polysomnography, and genetically defined disease targets to optimize patient outcomes.
- **Biomarker Collaboration**: Partners with Beacon Biosignals, utilizing their FDA 510(k)-cleared DREEM 3S device for biomarker capture in clinical studies.